Supplemental Oxygen for Airway Management
(OPTIMISE-2 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the optimal oxygen flow rate for young patients undergoing tracheal intubation, a procedure to assist breathing. Researchers aim to determine if a significant difference exists between low-flow and high-flow oxygen during this procedure. The trial compares two groups: one using low-flow nasal supplemental oxygen and the other using high-flow nasal supplemental oxygen. It seeks newborns and infants up to 52 weeks old who require intubation for planned or semi-urgent surgeries. As an unphased trial, this study provides a unique opportunity for patients to contribute to important research that could enhance future medical procedures.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this method is safe for airway management?
Research has shown that both low-flow and high-flow oxygen are generally safe during the insertion of a breathing tube. One study found that high-flow oxygen maintained better oxygen levels than low-flow oxygen in some situations. Despite this, low-flow oxygen remains widely used and is usually well-tolerated. Another study found that low-flow oxygen sometimes resulted in lower oxygen levels after tube insertion, but serious side effects were rare.
Overall, medical settings safely use both methods. While low-flow oxygen might not boost oxygen levels as effectively as high-flow oxygen, it remains a safe choice for many patients.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it explores different approaches to delivering supplemental oxygen during tracheal intubation, which is crucial for maintaining patient safety. The intervention group uses a low-flow nasal supplemental oxygen method, providing 0.2 L/kg/min FiO2 1.0, which could offer a gentler alternative to high-flow systems. On the other hand, the control group uses high-flow nasal supplemental oxygen at 2 L/kg/min FiO2 1.0, a more common practice. This trial aims to assess whether the low-flow method is as effective as the high-flow approach, potentially leading to more tailored oxygen delivery strategies during airway management.
What evidence suggests that this trial's treatments could be effective for airway management?
Research has shown that high-flow nasal oxygen (HFNO) helps maintain better oxygen levels during tracheal intubation. In this trial, participants in the control group will receive high-flow nasal supplemental oxygen. Studies have linked this to higher minimum oxygen levels, indicating generally better oxygen levels for patients. Conversely, participants in the intervention group will receive low-flow nasal supplemental oxygen, which has been associated with lower oxygen levels in some cases. For example, one study found that after intubation, only 12.9% of patients using high-flow oxygen experienced low oxygen levels, compared to 57.1% of those using low-flow oxygen. This evidence suggests that high-flow oxygen may be more effective at maintaining stable oxygen levels during intubation.678910
Who Is on the Research Team?
Thomas Riva, MD
Principal Investigator
University of Bern
Are You a Good Fit for This Trial?
This trial is for neonates and infants up to 52 weeks postconceptual age who need oral or nasal tracheal intubation for various medical procedures. Legal guardians must consent. It's not suitable for those outside this age range or without guardian consent.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Preparation and Induction
Eligible children are prepared for intubation according to local SOPs, including pre-oxygenation and administration of anesthesia and neuromuscular blocking agents.
Intubation Procedure
Tracheal intubation is performed with randomized low-flow or high-flow supplemental oxygen using the C-MAC video laryngoscope.
Follow-up
Participants are monitored for respiratory complications and other outcomes within the first 24 hours post-intubation.
What Are the Treatments Tested in This Trial?
Interventions
- High-flow nasal supplemental oxygen
- Laryngoscopy
- Low-flow nasal supplemental oxygen
- Tracheal Intubation
Laryngoscopy is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
- Airway management
- Endotracheal tube placement
- Anesthesia support
- Airway management
- Endotracheal tube placement
- Anesthesia support
- Airway management
- Endotracheal tube placement
- Anesthesia support
- Airway management
- Endotracheal tube placement
- Anesthesia support
- Airway management
- Endotracheal tube placement
- Anesthesia support
- Airway management
- Endotracheal tube placement
- Anesthesia support
Find a Clinic Near You
Who Is Running the Clinical Trial?
Thomas Riva
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Lead Sponsor
Istituto Giannina Gaslini
Collaborator
Royal Perth Hospital
Collaborator
University Hospital, Geneva
Collaborator
Centre Hospitalier Universitaire Vaudois
Collaborator
Luzerner Kantonsspital
Collaborator
Charite University, Berlin, Germany
Collaborator
Gaslini Children's Hospital
Collaborator
The Hospital for Sick Children
Collaborator